Terms: = Prostate cancer AND MKL1, BSAC, 57591, ENSG00000196588, Q969V6, MRTF-A
4 results:
1. Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size.
Li J; Foo JN; Schoof N; Varghese JS; Fernandez-Navarro P; Gierach GL; Quek ST; Hartman M; Nord S; Kristensen VN; Pollán M; Figueroa JD; Thompson DJ; Li Y; Khor CC; Humphreys K; Liu J; Czene K; Hall P
J Med Genet; 2013 Oct; 50(10):666-73. PubMed ID: 23825393
[TBL] [Abstract] [Full Text] [Related]
2. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/mkl1/SRF transcriptional pathway as potential anti-metastasis agents.
Bell JL; Haak AJ; Wade SM; Kirchhoff PD; Neubig RR; Larsen SD
Bioorg Med Chem Lett; 2013 Jul; 23(13):3826-32. PubMed ID: 23707258
[TBL] [Abstract] [Full Text] [Related]
3. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/mkl1 transcriptional pathway inhibitor, CCG-1423.
Evelyn CR; Bell JL; Ryu JG; Wade SM; Kocab A; Harzdorf NL; Showalter HD; Neubig RR; Larsen SD
Bioorg Med Chem Lett; 2010 Jan; 20(2):665-72. PubMed ID: 19963382
[TBL] [Abstract] [Full Text] [Related]
4. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.
Evelyn CR; Wade SM; Wang Q; Wu M; Iñiguez-Lluhí JA; Merajver SD; Neubig RR
Mol Cancer Ther; 2007 Aug; 6(8):2249-60. PubMed ID: 17699722
[TBL] [Abstract] [Full Text] [Related]
